Current status and recommendations for biomarkers and biobanking in neurofibromatosis

C Oliver Hanemann,Jaishri O Blakeley,Fabio P Nunes,Kent Robertson,Anat Stemmer-Rachamimov,Victor Mautner,Andreas Kurtz,Michael Ferguson,Brigitte C Widemann,D Gareth Evans,Rosalie Ferner,Steven L Carroll,Bruce Korf,Pierre Wolkenstein,Pamela Knight,Scott R Plotkin,REiNS International Collaboration,Shivani Ahlawat,Srivandana Akshintala,Jeffrey Allen,Simone Ardern-Holmes,Robert Avery,Amedeo Azizi,Dusica Babovic-Vuksanovic,Annette Bakker,Andrea Baldwin,Fred Barker,Amanda Bergner,Chetan Bettegowda,Sucharita Bhaumik,Larissa Bilaniuk,Kim Bischoff,Jaishri Blakely,Diana Bradford,Miriam Bredella,Wenli Cai,John Carino,Avneesh Chabra,Patricia Ciavarelli,Wade Clapp,Stephen Connor,Albert Cornelius,Tambra Dahlheimer,Stephanie Davis,Peter de Blank,Vidya Dhote,Joni Doherty,Eva Dombi,William Dudley,Rachel Ershler,Laura Fayad,Cristina Fernandez-Valle,Michael Fisher,Barbara Franklin,Giulia Fulci,Tracy Galloway,Kathy Gardner,Richard Gedrich,Marco Giovannini,Amy Goldstein,Anne Goodwin,Stephane Goutagny,David Gutmann,Theresa Hadlock,Chris Halpin,Kristina Hardy,Gordon Harris,Desiree Headley,Gena Heidary,Jonathan Heller,Cynthia Hingtgen,Trent Hummel,Susan Huson,Michael Jacobs,Jennifer Janusz,Diego Jaramillo,Justin Jordan,Allen Julian,Michel Kalamarides,Matthias Karajannis,Bonnie Klein-Tasman,Shannon Langmead,Theresa LaVallee,Fawn Leigh,Donita Lightner,Carol Lin,Robert Listernick,Grant Liu,Mevo Marco,Carole Marcus,Gabriella Mariani,Staci Martin,Vanessa Merker,Chris Moertel,Jill Morris,Katrina Morris,Kathryn North,Fabio Nunes,Roger Packer,Laura Papi,Allyson Parry,Neha Patel,Jonathan Payne,Karen Peluso,Sebastian Perreault,Scott Plotkin,Tina Poussaint,Nancy Ratner,Karlyne Reilly,Vincent Riccardi,Claas Rohl,Deborah Rukin Gold,La Rosa Salvatore,Laura Schaffner Gray,Elizabeth Schorry,Claire Semerjian,Monica Sheridan,Chie-Schin Shih,Carolyn Sidor,William Slattery 3rd,Miriam Smith,Kathy Sommer,Marigo Stathis,Matt Steensma,David Stevenson,Kari Struemph,Lara Sullivan,Mary Anne Tamula,Mary Thomas,Heather Thompson,James Tonsgard,Nicole Ullrich,Sharad Verma,David Viskochil,Ana-Maria Vranceanu,Ute Wahllander,Karin Walsh,Bradley Welling,Ralph Wenzel,Trish Whitcomb,Brigitte Widemann,Victoria Williams,David Wolf,Pamela Wolters,Kaleb Yohay
DOI: https://doi.org/10.1212/WNL.0000000000002932
IF: 9.9
2016-08-16
Neurology
Abstract:Objective: Clinically validated biomarkers for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis (SWN) have not been identified to date. The biomarker working group's goals are to (1) define biomarker needs in NF1, NF2, and SWN; (2) summarize existing data on biomarkers in NF1, NF2, and SWN; (3) outline recommendations for sample collection and biomarker development; and (4) standardize sample collection and methodology protocols where possible to promote comparison between studies by publishing standard operating procedures (SOPs). Methods: The biomarker group reviewed published data on biomarkers in NF1, NF2, and SWN and on biobanking efforts outside these diseases via literature search, defined the need for biomarkers in NF, and developed recommendations in a series of consensus meetings. Results: We describe existing biomarkers in NF and report consensus recommendations for SOP and a minimal clinical dataset to accompany samples derived from patients with NF1, NF2, and SWN in decentralized biobanks. Conclusions: These recommendations are intended to provide clinicians and researchers with a common set of guidelines to collect and store biospecimens and for establishment of biobanks for NF1, NF2, and SWN.
What problem does this paper attempt to address?